Ganirelix (Compound)

Synonyms:Ganirelix, Ganirelix acetate, Orgalutran, 124904-93-4, UNII-IX503L9WN0, 123246-29-7, CHEMBL1251, IX503L9WN0, Ganirelix Acetate Injection, RS-26306, CID 16134406, Ganirelixum, 129311-55-3, D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl-, Ganirelix [INN:BAN], Ganirelixum [INN-Latin], Orgalutran (TN), Ganirelix (INN), RS-26306-298, SCHEMBL19712192, CHEBI:135910, BDBM50102454, DB06785, D-Alaninamide, N-acetyl-3-(1-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-N6-(bis(ethylamino)methylene)-L-lysyl-L-prolyl-, D08010, Q5521314, Y-100038, Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-Tyr-D-Har(Et2)-Leu-Har(Et2)-Pro-DAla-NH2
Pubchem:PUBCHEM:16130957
Id:cedf3376-888f-53ff-a5c0-5c9f348c6268
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Ganirelix's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Ganirelix.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Ganirelix.

Results found

Linked to

 

Label

Description

 

Collection

Metadatata for ganirelix

Collection

DrugPage Collection: (DrugCentralID:01279; PubChem_CID:16130957, FILE=drugcentral_drug_01279.json)

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG


  • Collection

    DrugPage Collection: (DrugCentralID:01279; PubChem_CID:16130957, FILE=drugcentral_drug_01279.json)


  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.